OBJECTIVES The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Damman et al. Statistical analyses were performed using STATA (version 12.0, Stata Corp., College Station, Texas).
RESULTS
The mean age was 64 AE 11 years, 22% of participants were female, and the mean ejection fraction was 29 AE 6%. At screening, the mean eGFR was 70 AE 20 ml/min/ 1.73 m 2 and a total of 2,745 patients (33%) had CKD. In the subset of 1,872 patients with a screening UACR measurement, the median UACR was 1.0 mg/mmol (IQR: 0.4 to 3.2 mg/mmol) and a total of 441 patients (24%) had microalbuminuria or macroalbuminuria. JACC: HEART FAILURE VOL. 6, NO. 6, 2018
Damman et al. 8 normoalbuminuria to microalbuminuria at 1 month of follow-up, but this difference was not significant at 8 months after randomization (Online Figure 2 ). An increase of $25% in the UACR at 1 and 8 months was more common in the sacubitril/valsartan group (46% and 51% of patients, respectively), compared with the enalapril group (39% and 39%; p ¼ 0.004 and p < 0.001, respectively).
RELATIONSHIP BETWEEN CHANGE IN UACR AND
eGFR. In patients experiencing an increase of $25% in the UACR, sacubitril/valsartan was associated with a slower rate of decline in eGFR compared with enalapril, although there was no difference between treatments in patients experiencing no change or a decrease in UACR (Online Table 1 ).
RENAL OUTCOMES. The incidence of the prespecified renal outcome did not differ significantly between patients with or without CKD at screening and did not differ between treatment groups, either overall or by baseline CKD status ( Table 2) The incidence of the pre-specified renal outcome was higher in patients with microalbuminuria or macroalbuminuria at screening, but did not differ between treatment groups, either overall or by baseline albuminuria status, although all these analyses were based on small numbers of events ( (16) 291 (21) Higher UACR values at 30 days after random treatment assignment were associated with a higher incidence of the primary outcome in both treatment groups ( Figure 2B ). However, for any level of UACR at this time, the incidence of the primary outcome Values are n (%) unless otherwise noted. *First event contributing to composite. Tables 1 and 2. 95% CI: 0.24 to 0.80; p ¼ 0.008; p for interaction ¼ 0.52). which is potentially important therapeutically because conventional RAAS blockers are often withheld or withdrawn in patients with heart failure and renal dysfunction (19) .
Abbreviations as in

DISCUSSION
We also found that sacubitril/valsartan increased UACR compared with enalapril. Greater urinary albumin excretion has been associated with a more rapid worsening of renal function in patients with CKD (although it is not known whether this is also true in HFrEF) (20, 21) . However, the finding of an increase in the UACR with neprilysin inhibition is consistent with the effects of infused natriuretic peptides and earlier observations from a smaller study with sacubitril/valsartan in patients with heart failure and preserved ejection fraction (6, 22) . Of note, 
